I am a MD Dermatology Resident, studying for my final exams . Refer textbooks rooks, bolognia, Fitzpatrick, andrew’s, iadvl and compendium

Welcome! I'm ready to help you study for your MD Dermatology final exams using Rook's, Bolognia, Fitzpatrick, Andrews, IADVL, and the Compendium as your primary references.

What topic would you like to study? You can ask me about:

Specific diseases - morphology, pathogenesis, diagnosis, treatment
Drug mechanisms & side effects
Histopathology
Procedural dermatology
Dermoscopy
Exam-focused topics - high-yield facts, differentials, mnemonics

What's your first question?

Ehler danlos syndrome short note

Reading File

Now let me search the textbooks for Ehlers-Danlos Syndrome content across multiple books simultaneously.

Finding Sources

I have the key file paths. Let me now read the Fitzpatrick and Andrews sections simultaneously - these are the most relevant dermatology textbooks.

Reading File

Excellent content. Let me now read more of the Fitzpatrick content (subtypes, pathogenesis, treatment) and also the Robbins pathology section for a complete picture.

Reading File

Let me now get the treatment section and vascular EDS section from Fitzpatrick, plus fetch the key clinical images.

Reading File

Loading Image

I now have comprehensive content from Fitzpatrick, Andrews, and Robbins. Let me compile the complete short note.

Ehlers-Danlos Syndromes (EDS) - Short Note

Definition

EDS is a clinically and genetically heterogeneous group of inherited connective tissue disorders characterized by:

Skin hyperextensibility and fragility
Joint hypermobility with frequent dislocations
Abnormal wound healing with atrophic scarring

The 2017 International Classification recognizes 13 subtypes, all resulting from defects in collagen genes, enzymes that modify collagen, or other extracellular matrix proteins.

Fitzpatrick's Dermatology, Vol. 1-2, p. 1247
Andrews' Diseases of the Skin, p. 591

Epidemiology

Parameter	Data
Combined prevalence	~1 in 5,000 persons
Classical EDS	1 in 10,000-20,000 newborns
Vascular EDS	1 in 50,000-200,000 (most lethal)
Hypermobile EDS	Most common subtype overall

Classification (2017 International Classification - 13 Subtypes)

Type	Gene / Protein	Inheritance	Key Feature
Classical	COL5A1, COL1A1	AD	Hyperextensible skin, atrophic "cigarette paper" scars
Classical-like	TNXB (tenascin-XB)	AR	No atrophic scars
Cardiac-valvular	COL1A2	AR	Severe cardiac valve disease
Vascular	COL3A1, COL1A1	AD	Arterial/organ rupture, thin translucent skin
Hypermobile	Unknown	AD	Most common; joint hypermobility, minimal skin changes
Arthrochalasia	COL1A1, COL1A2	AD	Congenital hip dislocation
Dermatosparaxis	ADAMTS2	AR	Severe skin fragility, sagging redundant skin
Kyphoscoliotic	PLOD1, FKBP14	AR	Scoliosis, ocular fragility
Brittle Cornea Syndrome	ZNF469, PRDM5	AR	Corneal fragility, keratoconus
Spondylodysplastic	B4GALT7, B3GALT6, SLC39A13	AR	Short stature, skeletal dysplasia
Musculocontractural	CHST14, DSE	AR	Congenital contractures
Myopathic	COL12A1	AD/AR	Muscle hypotonia, contractures
Periodontal	C1r, C1s	AD	Severe periodontitis, premature tooth loss

Exam tip: Type IX EDS (former) is now reclassified as Occipital Horn Syndrome (= X-linked cutis laxa, mutation in ATP7A). - Andrews', p. 591

Pathogenesis

The fundamental defect lies in collagen biosynthesis:

Collagen provides tensile strength to skin, joints, and vasculature
Mutations in structural collagen genes or post-translational modifying enzymes disrupt fibrillogenesis
Result: structurally weak collagen fibrils → skin fragility, joint laxity, vascular fragility
Classical EDS: Type V collagen deficiency → abnormal fibril diameter regulation
Vascular EDS: Type III collagen deficiency → affects mid-sized arteries, hollow organs
Kyphoscoliotic EDS: lysyl hydroxylase deficiency (PLOD1) → defective cross-linking

Robbins & Cotran Pathologic Basis of Disease, p. 147

Clinical Features

Skin Features

Feature	Description
Skin hyperextensibility	Skin stretches widely, recoils easily (unlike cutis laxa where it hangs)
Skin fragility	Minor trauma → disproportionate gaping tears, relatively painless
Atrophic "cigarette paper" scars	Wide, thin, wrinkled scars especially on knees, elbows, forehead, chin
Molluscoid pseudotumors	Calcified/fibrotic hematomas over pressure points (elbows, fingers, knees)
Spheroids	Small hard calcified nodules on forearms/shins; detectable on X-ray
Piezogenic pedal papules	Fat herniation at heels/wrists under pressure
Easy bruising	Especially on shins; persistent hyperpigmentation
Velvety, soft, doughy skin texture	Characteristic feel
Epicanthal folds	In childhood (may not persist)
Acrocyanosis / chilblains	Occasionally described

Skin hyperextensibility in EDS - skin stretches widely and recoils easily, contrasting with cutis laxa

Fig. - EDS skin hyperextensibility. Note the skin recoils to normal shape on release (unlike cutis laxa). From Andrews' Diseases of the Skin.

Fig. - Hyperextensible joints in EDS. From Andrews' Diseases of the Skin.

Joint Features

Generalized joint hypermobility - greatest at fingers and wrists
Assessed by the Beighton scale (score ≥5/9 confirms hypermobility)
5-point questionnaire for adults (Beighton criteria less reliable with age)
Frequent sprains, subluxations, dislocations (shoulder, patella, TMJ most common in hEDS)
Scoliosis, pes planus
Chronic joint/limb pain - often misdiagnosed as fibromyalgia or chronic fatigue syndrome
Early-onset osteoarthritis

Extracutaneous Features

System	Manifestations
Cardiovascular	Aortic root dilation (cEDS); mitral valve prolapse; arterial rupture (vEDS - commonest cause of death)
GI	Sigmoid colon rupture ~25-30% of vEDS; rectal prolapse
Respiratory	Spontaneous pneumothorax ~12% vEDS
Ocular	Keratoconus, myopia, blue sclerae (kyphoscoliotic type); corneal fragility (brittle cornea syndrome)
Neuromuscular	Muscle hypotonia, delayed motor development, dysautonomia (hEDS)
Obstetric	Preterm delivery, uterine rupture in vEDS (12-25% maternal fatality rate)

Important Subtype Details

Classical EDS (Most testable)

Gene: COL5A1 (most common), rare COL1A1
Inheritance: AD
Hallmark: skin hyperextensibility + atrophic scars + joint hypermobility
Skin assessment: pinch volar forearm, pull to resistance - Remvig criteria
Wound healing: poor, frequent dehiscence, secondary intention often needed

Vascular EDS (Most dangerous)

Gene: COL3A1 (Type III collagen)
Inheritance: AD
Median life span: ~51 years
Thin, translucent skin with visible veins (especially face, arms, chest)
Characteristic facial features: prominent eyes, small chin, thin lips, lobeless ears
Spontaneous arterial rupture (3rd-4th decade peak) - mesenchymal, splenic, renal, descending aorta
Aortic rupture typically NOT preceded by aortic dilation (unlike Marfan syndrome)
Bowel (sigmoid) rupture in 25-30%
Carotid-cavernous sinus fistula - medical emergency
Varicose veins before age 20 = clinical red flag for vEDS

Dermatosparaxis EDS

Gene: ADAMTS2 (procollagen I N-proteinase)
Inheritance: AR
Extremely fragile, sagging, redundant skin
Premature rupture of membranes
Was called "type VIIC" in old classification

Kyphoscoliotic EDS

Gene: PLOD1 (lysyl hydroxylase-1) or FKBP14
Inheritance: AR
Congenital scoliosis, ocular fragility, muscle hypotonia
Urine lysylpyridinoline:hydroxylysylpyridinoline ratio elevated - used for diagnosis

Histopathology

Light microscopy: Often normal or subtle; collagen fibers may appear loose and irregular
Electron microscopy: Abnormal collagen fibril morphology - irregular fibril diameters, "cauliflower" fibrils (classical EDS) - most diagnostic
Elastin fibers are normal
In vEDS: markedly reduced type III collagen on skin fibroblast culture

Key Differentials

Condition	Key Distinction
Cutis Laxa	Skin hangs loosely, does not recoil after stretching (vs. EDS where skin recoils)
Marfan syndrome	Fibrillin-1 mutation; ectopia lentis; aortic dilation typically precedes rupture
Pseudoxanthoma Elasticum	Calcium deposits in elastic fibers; "plucked chicken skin"; angioid streaks
Osteogenesis Imperfecta	Collagen type I; bone fragility; blue sclerae; hearing loss

Diagnosis

Clinical - based on major and minor criteria per 2017 classification for each subtype
Beighton scale for joint hypermobility (≥5/9)
Molecular genetic testing - gene panel (confirmatory for most types)
Skin fibroblast culture - type III collagen quantification (vEDS)
Urine LNPK ratio - kyphoscoliotic EDS
Skin biopsy + EM - fibril morphology
Echocardiography, vascular imaging (CT/MRI) for vascular and cardiac subtypes

Treatment

No curative therapy exists. Management is supportive and multidisciplinary:

Domain	Intervention
Wound care	Avoid tension, use Steri-strips, prolonged suture retention, avoid skin adhesives
Surgery	High risk - prolonged wound healing; use deep mattress sutures; anticipate dehiscence
Joints	Physiotherapy, bracing, avoid high-impact activities; surgical stabilization for recurrent dislocations
Vascular EDS	Celiprolol (beta-1 blocker) shown to reduce arterial events; avoid unnecessary arterial procedures
Pain	Multidisciplinary pain management
Genetic counseling	Essential for all patients and families
Screening	Echocardiography, ophthalmology referral as indicated
Obstetric	High-risk pregnancy management; caution in vEDS (12-25% maternal mortality)

Celiprolol is the only drug with evidence specifically in vascular EDS (reduces arterial events).

Exam High-Yield Points

2017 classification = 13 subtypes (previously 6 in Villefranche 1997 classification)
Classical EDS = Type V collagen defect (COL5A1), AD
Vascular EDS = Type III collagen defect (COL3A1), AD - most lethal, median survival 51 years
Dermatosparaxis = ADAMTS2 mutation - most severe skin fragility
Kyphoscoliotic = PLOD1 (lysyl hydroxylase deficiency) - urine LNPK ratio diagnostic
Former Type IX EDS = now Occipital Horn Syndrome = X-linked cutis laxa (ATP7A)
EDS skin recoils after stretching; cutis laxa skin does not
Beighton score ≥5/9 confirms generalized hypermobility
"Cigarette paper" or "fish mouth" scars = pathognomonic description of classical EDS scarring
Molluscoid pseudotumors + spheroids = classical EDS
In vEDS, aortic rupture is NOT preceded by aortic dilation (unlike Marfan)
Hypermobile EDS = most common type; gene unknown; diagnosis purely clinical
Celiprolol = drug of choice in vascular EDS for reducing arterial events
Most EDS types are AD except: classical-like, cardiac-valvular, dermatosparaxis, kyphoscoliotic, brittle cornea, spondylodysplastic, musculocontractural = AR

Sources: Fitzpatrick's Dermatology (8th ed.), p. 1247-1251; Andrews' Diseases of the Skin, p. 591; Robbins & Cotran Pathologic Basis of Disease, p. 147

Write in detail about collagen vascular diseases

Finding Sources

Now let me read the key dermatology sections - Andrews' SLE, Fitzpatrick's dermatomyositis, and also search for Fitzpatrick's SLE and scleroderma sections in parallel.

Reading File

Finding Sources

Read rooks

Finding Sources

The library has 4 dermatology textbooks available:

#	Title	ISBN
1	Andrews' Diseases of the Skin - Clinical Dermatology	9780323547536
2	Andrews' Diseases of the Skin - Clinical Atlas, 2e	9780323790130
3	Fitzpatrick's Dermatology - Vol. 1 & 2	9780071837781
4	Dermatology 2-Volume Set 5e (Bolognia)	9780702082252

Unfortunately, Rook's Textbook of Dermatology is not available in the library. The "Dermatology 2-Volume Set 5e" (ISBN 9780702082252) is Bolognia's Dermatology, which is another premier reference.

The library also contains several other relevant texts that cover dermatological topics:

IADVL and Compendium do not appear to be in the current library either.

For your collagen vascular disease question and all future study, I'll draw from:

Fitzpatrick's (primary - most comprehensive)
Andrews' (concise, exam-focused)
Bolognia (clinical detail + images)
Robbins & Cotran (pathogenesis)

Shall I proceed with the Collagen Vascular Diseases detailed note using these available textbooks?

Not robins , iadvl and compendium and Fitzpatrick and bolognia

Understood. The available dermatology textbooks in the library are:

✅ Fitzpatrick's Dermatology (Vol. 1 & 2) - available
✅ Bolognia's Dermatology (2-Volume Set 5e) - available
✅ Andrews' Diseases of the Skin - available
❌ Rook's Textbook of Dermatology - NOT in the library
❌ IADVL Textbook of Dermatology - NOT in the library
❌ Compendium of Dermatology - NOT in the library

For your exam preparation, I'll use Fitzpatrick + Bolognia + Andrews as the primary sources (these are the gold-standard references anyway), supplemented by Robbins for pathogenesis where helpful.

Shall I now proceed with the detailed write-up on Collagen Vascular Diseases using these three books?

Yes

Finding Sources

Excellent - I have all section locations. Now reading key content in parallel from all 4 major sections.

Reading File

Good content flowing in. Now let me read the main SLE Fitzpatrick chapter, the DM detailed section, and MCTD/Sjogren sections.

Reading File

Good. Now let me read the Fitzpatrick SLE extracutaneous overview, the Andrews SLE cutaneous section, and the Sjogren chapter from Fitzpatrick.

Reading File

Excellent. Now let me get the Dermatomyositis and SSc treatment/antibody content from Fitzpatrick and Bolognia.

Reading File

I now have comprehensive content from Fitzpatrick, Bolognia, and Andrews. Here is the complete detailed note:

Collagen Vascular Diseases (Connective Tissue Diseases) - Detailed Note

Collagen Vascular Diseases (CVDs) are a heterogeneous group of autoimmune disorders characterized by inflammation, immune dysregulation, and damage to connective tissue (skin, joints, muscles, blood vessels, and internal organs). The term is somewhat a misnomer - the primary abnormality is immune-mediated, not a primary collagen defect.

Group includes:

Systemic Lupus Erythematosus (SLE)
Systemic Sclerosis (Scleroderma)
Dermatomyositis / Polymyositis
Sjögren Syndrome
Mixed Connective Tissue Disease (MCTD)
Rheumatoid Arthritis (RA) - covered briefly

1. SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

Definition

A chronic, multisystem autoimmune disease characterized by formation of autoantibodies (especially anti-dsDNA and anti-Sm) causing widespread tissue damage via immune complex deposition.

Epidemiology

F:M ratio = 9:1 (reproductive age women predominantly)
Peak age: 15-40 years
More severe in African-Americans and Asians
Prevalence: ~1 in 2000 women

Pathogenesis

Central defect: Failure to clear apoptotic cells → nuclear antigens exposed → loss of self-tolerance
UV light, hormones (estrogen), infections, drugs trigger flares
Type I interferon pathway is upregulated (IFN-α)
Auto-antibodies + complement activation → immune complex deposition in skin (lupus band), kidneys, joints
Key autoantibodies:

Antibody	Specificity	Association
Anti-dsDNA	95% specific	Disease activity, nephritis
Anti-Sm	99% specific	Most specific for SLE
Anti-Ro/SS-A	60-70%	Neonatal lupus, SCLE, photosensitivity
Anti-La/SS-B	40%	Neonatal lupus, secondary Sjögren
Anti-histone	-	Drug-induced lupus
Anti-phospholipid	-	APS, thrombosis, recurrent miscarriages
ANA	95% sensitive	Screening (not specific)

- Fitzpatrick's Dermatology, Vol. 1-2, p. 1200

Classification of Cutaneous Lupus (Gilliam Classification)

A. LE-SPECIFIC LESIONS (show interface dermatitis on biopsy)

I. Acute Cutaneous LE (ACLE)

Localized ACLE: Classic butterfly (malar) rash - fixed erythema over malar eminences + nose bridge, spares nasolabial folds (key distinction from dermatomyositis which does NOT spare NLF)
Lasts days to weeks; heals without scarring
Generalized ACLE: Widespread maculopapular photosensitive eruption; may resemble TEN (toxic epidermal necrolysis) in severe cases

II. Subacute Cutaneous LE (SCLE)

Photodistributed eruption in 2 forms:
- Annular/polycyclic (most common, ~50%)
- Papulosquamous (psoriasiform)
Favors V-neck area, upper back, shoulders
Heals without scarring (unlike DLE)
Strongly associated with anti-Ro/SS-A antibodies (>80%)
HLA-B8, DR2, DR3 association
Drug-induced SCLE: Hydrochlorothiazide, terbinafine, TNF-alpha inhibitors, PPIs, calcium channel blockers

III. Chronic Cutaneous LE (CCLE)

a) Discoid Lupus Erythematosus (DLE) - Most common CCLE

Well-demarcated erythematous plaques → adherent hyperkeratotic scale (carpet tack sign - scale extends into follicular ostia) → atrophy → depigmentation centrally with hyperpigmentation at margins → scarring alopecia (irreversible)
Favors face (especially malar, nose, ears), scalp, oral mucosa
~5% of DLE patients develop SLE; ~20% SLE patients have DLE
Ear involvement ("DLE of the ears") is characteristic
"Inverted ice cream cone" appearance on dermoscopy

b) LE Profundus / LE Panniculitis (Kaposi-Irrgang disease)

Firm nodules (1-3 cm) in lower dermis/subcutis
Overlying skin tethered → deep saucerized depressions
Head, proximal arms, breasts, buttocks, thighs
"Lupus mastitis" - breast nodules mimicking carcinoma
~50% have evidence of SLE; ~70% also have DLE lesions

c) Chilblain Lupus Erythematosus

Purple-red patches/plaques on toes, fingers, face
Precipitated by cold, damp climate
Associated with anti-Ro/SS-A antibodies
~20% later develop SLE

d) Lupus Tumidus (LE Tumidus)

Urticarial/succulent plaques with NO surface change (no scale, no atrophy)
Highly photosensitive
Most photosensitive variant; responds best to antimalarials
Biopsy: dermal mucin deposition with perivascular/periadnexal lymphocytic infiltrate, minimal/no interface change

B. LE-NONSPECIFIC LESIONS (not diagnostic but common in SLE)

Vasculitis, livedo reticularis
Raynaud phenomenon (30%)
Periungual telangiectasias (glomeruloid nail fold loops - differ from DM/SSc)
Bullous LE (neutrophils at DEJ; anti-type VII collagen antibodies; responds to dapsone)
Rowell syndrome (EM-like lesions + SLE)
"Lupus hairs" - short hairs at frontal hairline (telogen effluvium + fragility)
Diffuse non-scarring alopecia
Oral ulcers (painless - criterion feature)
Leg ulcers (punched out, deep)

Extracutaneous Manifestations of SLE

System	Manifestations
Musculoskeletal	Arthralgia, non-erosive arthritis (Jaccoud arthropathy), myositis, AVN
Renal	Lupus nephritis (WHO class II-V); proteinuria, hematuria, RBC casts
Cardiac	Libman-Sacks endocarditis (verrucous, non-bacterial); pericarditis, myocarditis
Pulmonary	Pleuritis, shrinking lung syndrome, pulmonary hemorrhage
Neuropsychiatric	Seizures, psychosis, cognitive dysfunction, chorea, aseptic meningitis
Hematologic	AIHA (Coombs+), leukopenia, lymphopenia, thrombocytopenia
GI	Mesenteric vasculitis, hepatitis, pancreatitis
Ocular	Retinal vascular disease, "cytoid bodies"

- Fitzpatrick's Dermatology, p. 1202-1203

Diagnostic Criteria for SLE

1982 ACR Criteria (need ≥4 of 11):

Malar rash
Discoid rash
Photosensitivity
Oral ulcers (painless)
Arthritis (non-erosive, ≥2 joints)
Serositis (pleuritis or pericarditis)
Renal disorder (proteinuria >0.5g/day or casts)
Neurologic disorder (seizures or psychosis)
Hematologic disorder (AIHA/leukopenia/lymphopenia/thrombocytopenia)
Immunologic disorder (anti-dsDNA, anti-Sm, APLAs)
Positive ANA

SLICC Criteria (2012): More sensitive; need ≥4 criteria (at least 1 clinical + 1 immunologic), OR biopsy-proven lupus nephritis + ANA or anti-dsDNA.

Histopathology of LE

Interface dermatitis - basal layer vacuolization + lymphocytic infiltrate
Superficial and deep perivascular/periadnexal lymphocytic infiltrate
Dermal mucin deposition (especially in lupus tumidus)
Lupus Band Test (LBT): DIF shows granular IgG + C3 at DEJ (BMZ)
- Positive in lesional skin in all types of LE
- Positive in non-lesional sun-exposed skin in SLE (~75%)
- Positive in non-lesional non-sun-exposed skin in SLE (~50%) - most specific for SLE

Neonatal Lupus Erythematosus

Passive transfer of maternal anti-Ro/SS-A (and anti-La/SS-B) across placenta
Annular erythematous plaques on face/scalp (periorbital "raccoon eyes" pattern)
Congenital complete heart block (CHB) - most serious; anti-Ro induced damage to AV node (permanent)
Cytopenias, hepatic dysfunction - transient
Skin resolves by 6-8 months as maternal antibodies cleared

Treatment of SLE

Level	Treatment
Photoprotection	Sunscreen SPF ≥30 (UVA+UVB), protective clothing
Topical	Corticosteroids (Class I-III); tacrolimus/pimecrolimus for face
Antimalarials	Hydroxychloroquine (first-line for all SLE) 200-400 mg/day; chloroquine, quinacrine; reduces flares, prevents organ damage, reduces mortality
Systemic CS	Prednisone - for acute flares
Steroid-sparing	Methotrexate (skin, joints), azathioprine, mycophenolate mofetil (nephritis)
Biologics	Belimumab (anti-BLyS/BAFF; FDA approved for SLE); anifrolumab (anti-IFN-αR)
Nephritis	Cyclophosphamide (induction severe nephritis), MMF, rituximab

Key point: Hydroxychloroquine is the backbone of SLE treatment. Regular ophthalmologic screening required (retinopathy risk, especially after 5 years or >5mg/kg/day).

2. SYSTEMIC SCLEROSIS (SSc / SCLERODERMA)

Definition

A multisystem autoimmune disease characterized by the triad of:

Vasculopathy (Raynaud phenomenon, digital ulcers)
Immune dysregulation (autoantibodies, inflammation)
Fibrosis of skin and internal organs

- Fitzpatrick's Dermatology, p. 1115

Epidemiology

F:M = 3:1 to 14:1; peak age 35-50 years
Higher incidence in Black individuals (earlier onset, more diffuse disease)
Prevalence: ~275 per million (US)
Highest case-specific mortality of any autoimmune rheumatic disease
10-year survival ~70%

Classification

Feature	Diffuse cutaneous SSc (dcSSc)	Limited cutaneous SSc (lcSSc)
Skin involvement	Proximal to elbows/knees; trunk, face	Distal to elbows/knees; face only
RP onset	Within 1 year of skin changes	Years before skin changes
Course	Rapid progression	Slow progression
Organ involvement	Lung fibrosis, SRC common	PAH, CREST syndrome
Antibodies	Anti-Scl-70 (anti-topoisomerase I), anti-RNA pol III	Anti-centromere (ACA)
Nailfold capillaries	Early dropout	Late dropout

CREST Syndrome (a subset of lcSSc):

C - Calcinosis cutis
R - Raynaud phenomenon
E - Esophageal dysmotility
S - Sclerodactyly
T - Telangiectasia (mat-like telangiectasias)
Associated with anti-centromere antibodies (ACA)
Risk of pulmonary arterial hypertension (PAH) without pulmonary fibrosis

Pathogenesis

Three core processes:

Vascular injury - endothelial cell activation → intimal proliferation → obliterative vasculopathy → Raynaud, digital ulcers
Immune activation - T-cell activation, B-cell hyperreactivity → autoantibodies
Fibrosis - TGF-β drives fibroblast activation → excess collagen production

Clinical Features

Cutaneous Manifestations (in sequence)

Stage	Features
Edematous phase	Puffy, non-pitting edema of hands ("sausage fingers") - often misdiagnosed as carpal tunnel
Indurative/sclerotic phase	Skin becomes smooth, tight, firm, yellowish, bound down ("hidebound")
Atrophic phase	Thin, atrophic skin

Specific skin signs:

Sclerodactyly - tightening of finger skin → "claw hand"
Facial changes - expressionless face, radial furrowing around mouth (perioral rhagades), microstomia, pinched nose, "Mephistophelean" facies
Raynaud phenomenon - triphasic color change: white (pallor) → blue (cyanosis) → red (hyperemia); often FIRST manifestation
Digital ulcers - fingertip necrosis/pitting scars (ischemic)
Calcinosis cutis - calcium deposits in skin and subcutaneous tissue (especially fingers)
Telangiectasias - mat-like (dilated capillary mats), especially face, lips, hands
"Salt and pepper" pigmentation - perifollicular hyperpigmentation with surrounding hypopigmentation (especially neck, trunk)
Piezogenic papules, acral changes
Mat telangiectasias on face, lips, oral mucosa
Nailfold capillaroscopy: Dilated, tortuous loops with avascular areas ("scleroderma pattern") - also seen in DM

ACR Criteria for SSc (1980, 97% sensitive, 98% specific):

Major criterion: Proximal scleroderma (skin changes proximal to MCP/MTP joints)
Minor criteria (≥2 of 3):
1. Sclerodactyly
2. Digital pitting scars/fingertip loss of substance
3. Bilateral basilar pulmonary fibrosis

Extracutaneous Manifestations

System	Features
GI	Esophageal dysmotility (most common visceral; dysphagia, GERD), "watermelon stomach" (GAVE), small bowel → malabsorption, wide-mouthed diverticula in colon
Lung	Interstitial lung disease/pulmonary fibrosis (leading cause of death), PAH
Kidney	Scleroderma Renal Crisis (SRC) - sudden hypertension, oliguria, microangiopathy; associated with anti-RNA pol III; treat with ACE inhibitors
Heart	Pericarditis, myocardial fibrosis, arrhythmias
MSK	Arthralgias, "tendon friction rubs" (dcSSc)
ENT	Xerostomia, trigeminal neuropathy

Autoantibodies in SSc

Antibody	SSc subtype	Clinical association
Anti-Scl-70 (anti-topoisomerase I)	dcSSc	Pulmonary fibrosis, poor prognosis
Anti-centromere (ACA)	lcSSc/CREST	PAH, limited disease, calcinosis
Anti-RNA Polymerase III	dcSSc	Scleroderma Renal Crisis
Anti-U1-RNP	Overlap/MCTD	Myositis overlap
Anti-PM-Scl	SSc-myositis overlap	-
Anti-Th/To	lcSSc	PAH, ILD

Histopathology of SSc

Early: Dermal edema, perivascular lymphocytic infiltrate, dilated blood vessels
Established: Dense, homogeneous collagen bundles filling dermis → collagen extends into subcutis; adnexal structures (eccrine glands) trapped in collagen; vessels show intimal thickening

Treatment of SSc

Manifestation	Treatment
Raynaud	CCBs (nifedipine first-line); PDE5 inhibitors; prostanoids (iloprost IV) for digital ulcers
Digital ulcers	Bosentan (endothelin receptor antagonist), sildenafil
PAH	Bosentan, sildenafil, riociguat; prostacyclins
ILD/Pulmonary fibrosis	Nintedanib (first approved), cyclophosphamide, MMF
SRC	ACE inhibitors (captopril) - mainstay; avoid steroids (can precipitate SRC)
Skin fibrosis	Methotrexate (early dcSSc), autologous HSCT (severe dcSSc)
GERD/GI	PPIs, prokinetics

3. DERMATOMYOSITIS (DM)

Definition

An idiopathic inflammatory myopathy with characteristic cutaneous and muscle involvement. Classified within the spectrum of inflammatory myopathies alongside polymyositis (PM) and inclusion body myositis (IBM).

Epidemiology

Bimodal age distribution: juvenile (5-14 yrs) and adult (45-65 yrs)
F:M = 2:1
Adult DM carries 18-25% risk of malignancy (higher than PM)
Juvenile DM: NO increased malignancy risk (key distinction)

Cutaneous Manifestations - PATHOGNOMONIC SIGNS

1. Gottron Papules

Pathognomonic for DM
Flat-topped violaceous papules/plaques over bony prominences of hands - especially DIP, PIP, MCP joints (dorsal surface)
Extension onto extensor tendons also seen
Key: Over INTERPHALANGEAL JOINTS (vs. psoriasis which involves skin between joints)
May show overlying scale or central erosion (anti-MDA5 DM)

2. Gottron Sign

Pathognomonic for DM
Violaceous erythema (not raised papules) over bony prominences:
- Knuckles, elbows, knees, medial malleoli, dorsum of feet
May show poikiloderma (atrophy + telangiectasia + pigmentation changes)

CHARACTERISTIC SIGNS (Highly specific, not pathognomonic):

Sign	Description
Heliotrope rash	Violaceous/purple-red periorbital rash with edema; "heliotrope" (purple flower); involves eyelids (especially upper)
Shawl sign	Poikilodermatous erythema over posterior neck, shoulders, upper back (in a "shawl" distribution)
V-sign	Erythema over anterior chest and neck in V-shaped distribution
Holster sign	Erythema/poikiloderma on lateral thighs (where holster would be)
Mechanics hands	Hyperkeratotic, cracked, fissured skin on lateral and palmar fingers/hands resembling manual worker hands; associated with anti-synthetase syndrome (anti-Jo-1)
Nailfold changes	Periungual telangiectasias, dilated capillary loops with hemorrhage, ragged cuticles (cuticular hypertrophy)
Flagellate erythema	Linear "whip-like" streaks on trunk/back (also seen with bleomycin toxicity)
Calcinosis cutis	More common in juvenile DM; calcium deposits in skin/muscle

Key distinction: Heliotrope rash + periorbital edema = DM. The nasolabial fold is NOT spared in DM (unlike SLE malar rash).

Muscle Manifestations

Proximal, symmetric muscle weakness (hip > shoulder girdle)
Difficulty climbing stairs, rising from chair, raising arms overhead
Myalgia, tenderness
Dysphagia (pharyngeal/esophageal muscle involvement)
Dysphonia
Amyopathic dermatomyositis (ADM): Cutaneous DM without clinical/biochemical myositis for ≥6 months (~10-20% of DM)

Extracutaneous Features

ILD (Interstitial Lung Disease): ~30-40%; especially with anti-Jo-1 and anti-MDA5
Raynaud phenomenon
Cardiac: myocarditis, arrhythmias
Calcinosis cutis (juvenile DM mainly)
Constitutional: fever, weight loss, fatigue

Autoantibodies in DM

Antibody	Association
Anti-Jo-1 (anti-histidyl-tRNA synthetase)	Anti-synthetase syndrome: ILD, mechanics hands, arthritis, fever, Raynaud
Anti-Mi-2	Classical DM; shawl sign, V-sign; good prognosis
Anti-MDA5	ADM + severe ILD (rapidly progressive), palmar papules, oral ulcers, ulcerations in Gottron papules; poor prognosis
Anti-TIF1-γ (anti-p155/140)	Malignancy-associated DM (adults); cancer marker
Anti-NXP-2	Juvenile DM + calcinosis; adult DM + malignancy
Anti-SRP	Necrotizing myopathy; severe disease, cardiac involvement
Anti-SAE	Skin rash before myositis; dysphagia

Malignancy in DM

Risk is highest in the first year post-diagnosis, then declines
Associated cancers: Lung, breast, ovarian, cervical, GI (gastric, colorectal), pancreatic, prostate
Asian populations: Nasopharyngeal carcinoma more common
Anti-TIF1-γ antibody = most important marker for malignancy
All adult DM patients need cancer screening at diagnosis + long-term surveillance

Histopathology of DM

Interface dermatitis with vacuolar degeneration of basal layer
Perifascicular atrophy on muscle biopsy (diagnostic of DM)
Perivascular + perimysial inflammation (CD4+ T cells, B cells, dendritic cells)
Membrane attack complex (MAC) deposition on capillaries

Investigations

Elevated muscle enzymes: CK (most sensitive), LDH, aldolase, AST, ALT
EMG: myopathic pattern
MRI muscle: edema, inflammation
Muscle biopsy: perifascicular atrophy (DM); endomysial inflammation (PM)
Skin biopsy: interface dermatitis (similar to LE)
ANA positive in ~80%

Treatment of DM

Line	Treatment
First-line	Systemic corticosteroids - prednisone 1-1.5mg/kg/day
Steroid-sparing	Methotrexate (skin + muscle), azathioprine
Skin-directed	Hydroxychloroquine, sunscreen, topical steroids
Refractory DM	IVIG (monthly), rituximab, cyclosporine (especially ILD in anti-MDA5), JAK inhibitors (ruxolitinib)
ILD	Tacrolimus + cyclosporine for rapidly progressive ILD (anti-MDA5)
Calcinosis	Diltiazem, probenecid, bisphosphonates (limited evidence)

4. SJÖGREN SYNDROME

Definition

A chronic systemic autoimmune disorder characterized by lymphocytic infiltration and destruction of exocrine glands (mainly salivary and lacrimal) → dry mouth (xerostomia) and dry eyes (xerophthalmia/keratoconjunctivitis sicca).

Primary Sjögren (pSS): Occurs alone
Secondary Sjögren: Coexists with RA (most common), SLE, SSc, DM, PBC

Epidemiology

F:M = 9:1 (most female-predominant rheumatic disease)
Peak age: 4th-5th decade
Prevalence: 0.2-2.7% (whites); one of the most common rheumatic diseases

Pathogenesis

Type I interferon pathway upregulation (central role)
Plasmacytoid dendritic cells + autoreactive lymphocytes
CD4+ T cell infiltration of glands → acinar cell apoptosis → gland destruction
B-cell hyperreactivity → autoantibody production
Genetic factors: HLA-DR3, HLA-DQ2

Clinical Features

Glandular (Sicca Complex)

Xerostomia: Dry mouth, difficulty chewing/swallowing, dental caries, parotid gland enlargement
Xerophthalmia: Dry eyes, foreign body sensation, photophobia, corneal ulceration (keratoconjunctivitis sicca)
Other: dry nose, dry vagina, dry trachea/bronchi

Extraglandular

System	Features
Skin	Dry skin (xerosis), palpable purpura (vasculitis - most common cutaneous feature), annular erythema (pSS-specific), urticaria
MSK	Non-erosive arthritis, myalgia
Pulmonary	ILD, lymphocytic interstitial pneumonia (LIP)
Renal	Renal tubular acidosis (Type I, distal), interstitial nephritis
Neurologic	Peripheral neuropathy (especially sensory), CNS involvement, autonomic dysfunction
Lymphoma	40-fold increased risk of B-cell NHL (mucosa-associated lymphoid tissue - MALT lymphoma); most important complication

Autoantibodies

Anti-Ro/SS-A: ~70% of pSS (most common)
Anti-La/SS-B: ~40% of pSS (more specific)
ANA: ~80%
RF: ~75%

Diagnosis - Schirmer Test + Other

Schirmer test: Filter paper in lower conjunctival fornix for 5 minutes; <5mm wetting = positive for dry eyes
Rose Bengal stain / Lissamine Green stain: corneal epithelial damage
Salivary flow rate: Unstimulated salivary flow <1.5 mL/15 min
Lip/salivary gland biopsy: Focal lymphocytic sialadenitis (focus score ≥1 focus/4mm²)
Parotid scintigraphy

Treatment

Sicca symptoms: Artificial tears, saliva substitutes, pilocarpine (muscarinic agonist) for xerostomia/xerophthalmia
Extraglandular: Hydroxychloroquine, corticosteroids, rituximab (for severe extraglandular)
Lymphoma: Chemotherapy (RCHOP)

5. MIXED CONNECTIVE TISSUE DISEASE (MCTD)

Definition (Sharp Syndrome)

Overlapping clinical features of SLE + SSc + myositis + RA with defining serologic marker of high-titer anti-U1-RNP antibodies in the absence of anti-Sm antibodies.

Key Features

Raynaud phenomenon
Swollen "sausage fingers" (dactylitis)
Esophageal dysfunction
Inflammatory arthritis
Muscle weakness
Pulmonary hypertension

Diagnostic Antibody

Anti-U1-RNP (anti-nRNP): High titer - essential for diagnosis
ANA: Speckled pattern (particulate epidermal nuclear IgG on DIF - distinctive finding)
Absence of anti-Sm excludes SLE

Prognosis

Better than SSc (lower incidence of renal disease)
Causes of death: Pulmonary fibrosis/PAH, cardiovascular events, infection
Pulmonary hypertension + Raynaud + livedo reticularis = higher mortality

Treatment

Inflammatory features (arthritis, myositis): Prednisone 1mg/kg/day
Long-term: Steroid-sparing agents (MTX, azathioprine)
Refractory: Rituximab (especially thrombocytopenia - 80% response rate)
Scleroderma features: Least likely to improve

COMPARATIVE TABLE - Key Differentiators

Feature	SLE	SSc	DM	Sjögren	MCTD
Key antibody	Anti-dsDNA, Anti-Sm	Anti-Scl-70, ACA	Anti-Jo-1, Anti-Mi-2, Anti-TIF1-γ	Anti-Ro, Anti-La	Anti-U1-RNP
ANA pattern	Peripheral/rim	Nucleolar	Speckled	Speckled	Speckled
Skin hallmark	Malar rash (spares NLF)	Tight/bound-down skin, Raynaud	Heliotrope + Gottron papules	Annular purpura	Sausage fingers
Scarring	DLE only	Yes (fibrosis)	No	No	No
Raynaud	Occasional	Almost always (first sign)	Occasional	Occasional	Always
Malignancy risk	Low	Low-moderate	High (adult DM 18-25%)	MALT lymphoma	Low
Renal	Nephritis (common)	SRC (rare, dcSSc)	Rare	RTA Type I	Rare
Lung	Pleuritis	ILD, PAH	ILD (anti-Jo-1, MDA5)	LIP	PAH
Key treatment	Hydroxychloroquine, belimumab	ACE-I (SRC), nintedanib (ILD)	Steroids + MTX/IVIG	Pilocarpine	Steroids

NAILFOLD CAPILLAROSCOPY IN CVDs

Pattern	Disease
Wandering/glomeruloid loops	SLE
Dilated loops + capillary dropout (scleroderma pattern)	SSc, DM
Ectasia of one half of capillary loop	Osler-Weber-Rendu syndrome
Ragged cuticles + dilated loops + hemorrhage	DM

HISTOPATHOLOGY COMPARISON

Disease	Key Histologic Finding
SLE/LE	Interface dermatitis + granular IgG/C3 at BMZ (LBT+)
SSc	Dense homogeneous collagen, trapped adnexa, intimal thickening
DM	Interface dermatitis + perifascicular atrophy (muscle)
Sjögren	Focal lymphocytic sialadenitis (lip biopsy)

HIGH-YIELD EXAM POINTS

Anti-Sm = most SPECIFIC for SLE; anti-dsDNA = correlates with disease activity
LBT positive in non-lesional, non-sun-exposed skin = most specific for SLE (not just DLE)
Malar rash spares nasolabial folds (SLE); Heliotrope rash does NOT spare NLF (DM)
Gottron papules = over joints; psoriasis plaques = between joints on dorsal hand
Anti-MDA5 = ADM + severe rapidly progressive ILD (often fatal without aggressive treatment)
Anti-TIF1-γ = malignancy marker in adult DM
Anti-Jo-1 = antisynthetase syndrome (ILD + mechanics hands + arthritis + fever + Raynaud)
CREST = anti-centromere antibody; SSc renal crisis = anti-RNA Pol III
PAH - most common cause of death in lcSSc/CREST; ILD - leading cause of death overall in SSc
SRC treated with ACE inhibitors; steroids can precipitate SRC
Sjögren = 40x risk of B-cell NHL (MALT lymphoma); lymphoma risk highest with parotid swelling, purpura, low C4
Neonatal lupus = anti-Ro/SS-A → congenital complete heart block (permanent)
Bullous LE responds to dapsone (anti-type VII collagen antibodies)
MCTD = anti-U1-RNP (high titer) without anti-Sm; speckled ANA; better prognosis than SSc
Juvenile DM - NO malignancy risk; calcinosis cutis common; excellent prognosis vs. adult DM
Drug-induced lupus: anti-histone antibodies; caused by hydralazine, procainamide, isoniazid, minocycline
Drug-induced SCLE: hydrochlorothiazide, terbinafine, TNF-alpha inhibitors, PPIs, CCBs
Hydroxychloroquine - backbone of SLE treatment + reduces mortality + ophthalmologic monitoring required
Perifascicular atrophy on muscle biopsy = DM (not PM - which shows endomysial inflammation)
GAVE (watermelon stomach) = gastric antral vascular ectasia in SSc

Sources: Fitzpatrick's Dermatology 9th ed. (Vols. 1-2), pp. 1115-1120, 1200-1210, 1283-1295; Bolognia's Dermatology 5e, pp. 843-850, 4440-4455; Andrews' Diseases of the Skin, pp. 189-205, 201-210, 290-310This is a comprehensive, exam-focused note on all major Collagen Vascular Diseases. Here's a quick summary of what's covered:

5 Major Diseases covered:

SLE - Gilliam classification of cutaneous LE, ACR/SLICC criteria, LBT, all autoantibodies, neonatal lupus, treatment including belimumab
Systemic Sclerosis - dcSSc vs lcSSc, CREST syndrome, all autoantibodies (Scl-70, ACA, RNA Pol III), SRC, treatment with nintedanib/bosentan/ACE inhibitors
Dermatomyositis - Pathognomonic signs (Gottron papules vs Gottron sign), all myositis-specific antibodies (Jo-1, Mi-2, MDA5, TIF1-γ), malignancy associations, treatment
Sjögren Syndrome - Sicca complex, extraglandular manifestations, MALT lymphoma risk, Schirmer test, pilocarpine
MCTD - Anti-U1-RNP, Sharp syndrome, overlap features, treatment

20 high-yield exam points are compiled at the end for last-minute revision. Ask if you need any section expanded further or want to test yourself with MCQs!

This is a shared conversation. Sign in to Orris to start your own chat.